CHANHASSEN, Minn., Feb. 25, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today ...
Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma CHANHASSEN, Minn., May 15, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a ...
Patients with high-risk features undergoing elective PCI and treated with the more-potent antiplatelet agent ticagrelor (Brilinta; AstraZeneca) instead of clopidogrel fared no better with respect to ...
Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma
The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment. Glioblastoma is a highly infiltrative ...
A Chanhassen-based medical company has raised $52 million in its quest to treat an aggressive form of brain cancer. Late last week, Alpheus Medical Inc. announced that it closed its Series B funding ...
Chanhassen-based Alpheus Medical has raised $14 million to advance its development of sonodynamic therapy (SDT) to treat large aggressive brain tumors. Founded just a year ago, in 2021, Alpheus ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Alpheus’ therapy centers on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results